Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)
Milestone Pharmaceuticals Inc. entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia—a rapid heart rhythm disturbance that can be frightening, disruptive, and costly when it sends patients to emergency care. GlobeNewswire
